Mesoblast Ltd SP ADR (MBLTY) 12.3300 $MBLTY
Mesoblast Lists On Nasdaq
GlobeNewswire - Sun Nov 15, 5:46PM CST
Mesoblast Limited (ASX:MSB) (NASDAQ:MESO) today announced it had listed on the Nasdaq Global Market on 13 November under the symbol 'MESO'.
MESO: 3.91 (-0.17), MSB: 10.35 (-0.05)
Nasdaq Welcomes Mesoblast Limited to The Nasdaq Stock Market
GlobeNewswire - Fri Nov 13, 2:59PM CST
Nasdaq, Inc. (Nasdaq:NDAQ) announced that trading of Mesoblast Limited (Nasdaq:MESO) commenced on The Nasdaq Stock Market on November 13, 2015.
MESO: 3.91 (-0.17), MSB: 10.35 (-0.05), NDAQ: 64.92 (+0.18)
Mesoblast Announces Pricing Of Public Offering On Nasdaq
GlobeNewswire - Fri Nov 13, 7:39AM CST
Mesoblast Limited (NASDAQ:MESO) (ASX:MSB), a world leader in the development of innovative cell-based medicines, today announced the pricing of its public offering of 7,479,617 American Depositary Shares (ADSs), at a public offering price of US$8.00 per ADS, before underwriting discounts and commissions. In addition, Mesoblast has granted the underwriters a 30-day option to purchase up to an additional 1,121,942 ADSs at the public offering price to cover over-allotments, if any. Mesoblast expects gross proceeds before deducting underwriting discounts and commissions and expenses of approximately US$59.8 million or A$83.9 million, or US$68.8 million or A$96.5 million if the underwriters exercise their over-allotment option. The ADSs are expected to begin trading on the Nasdaq Global Market on 13 November, 2015 under the symbol 'MESO'.
MESO: 3.91 (-0.17), MSB: 10.35 (-0.05)
Key United States Patent Granted For The Treatment Of Heart Diseases, Stroke And Other Vascular Conditions
GlobeNewswire - Tue Oct 27, 8:07PM CDT
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Patent and Trademark Office (USPTO) has granted a key patent covering the use of the Company's proprietary adult Mesenchymal Precursor Cells (MPCs) for the formation and repair of blood vessels in ischemic tissues.
MSB: 10.35 (-0.05)
U.S. Markets for Biologic and Tissue Engineered Devices 2015 - Cardiovascular and Neurological Products Analysis
M2 - Tue Oct 27, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fghmqn/u_s_markets_for) has announced the addition of the "U.S. Markets for Biologic and Tissue Engineered Devices - Cardiovascular and Neurological Products" report to their offering. Tissue engineering, or regenerative medicine, represents a promising therapeutic possibility for the treatment of aggressive and deadly diseases. Cellular therapies for cardiovascular disease (CVD) and neurological disease represent potential billion dollar markets that could offer a viable therapeutic option for a sizable patient population that has exhausted other therapeutic alternatives. Over 35 novel cellular therapies for cardiovascular and neurological disease are currently in development internationally, and in the United States (U.S.). The scope of the analysis of this report covers companies developing novel cellular therapeutics for the treatment of debilitating and deadly diseases that currently lack adequate therapeutic intervention. Cardiovascular disease-related conditions with cellular therapies in development are discussed in Chapter 2 of this report, which covers acute myocardial infarction, critical limb ischemia, heart failure, and bioengineered vascular grafts. Neurological conditions/diseases discussed in Chapter 3 of this report include Alzheimer's disease, ischemic stroke, Parkinson's disease, and spinal cord injury. Content included in this report includes: - Emerging cellular therapies for cardiovascular and neurological diseases - Companies and biotech firms developing novel cellular therapies - A prospective regulatory approval forecast for cellular therapy products currently in development for cardiovascular and neurological diseases - A speculative market analysis predicting the potential overall market values for cardiovascular and neurological disease stem cell therapies. Key Topics Covered: Executive Summary 1. Tissue Engineering and Cellular Therapy Tools and Techniques 1.1 Biomaterials 1.2 Cell Culture Technology 1.3 Stem Cell Technology 1.4 Immunoisolation Technology 2. Emerging Applications of Tissue Engineering and Cell Transplantation in Cardiovascular Disease Management 2.1 Cellular Therapy and Tissue Engineering 2.2 Cellular Therapy Administration 2.3 Clinical Experience with Stem Cell-Based Myocardial Tissue Repair and Regeneration 2.4 Cellular Therapies for Myocardial Repair and Regeneration in Development 2.5 Emerging Cellular Therapies for Limb Salvage in Critical Limb Ischemia Patients 2.6 Bioengineered Vascular Conduits 2.7 Current and Emerging U.S. Market for Cardiovascular Disease-Related Tissue Engineering and Cellular Therapy Products 3. Emerging Applications of Tissue Engineering and Cell Transplantation in Neurological Disease Management 3.1 Types of Cells Used for Cellular Therapies in Development 3.2 Emerging Stem Cell-Based Therapies for Alzheimer's Disease 3.3 Emerging Stem Cell-Based Therapies for Parkinson's Disease 3.4 Emerging Stem Cell-Based Therapies for Spinal Cord Injury 3.5 Emerging Stem Cell-Based Therapies for Post-Ischemic Stroke 3.6 Potential U.S. Market for Neurological Disease-Related Cellular Therapy Products Appendix: Company Listing Bibliography Companies Mentioned - Athersys - Baxter - Bioheart, Inc. - Biomet Biologics - Bukwang Pharmaceutical - Bundang CHA Hospital - Capricor Therapeutics - Chinese Academy of Military Medical Sciences - Cytori Therapeutics - Ecron Acunova - Fondazione IRCCS Ca'Granda, Ospedale Maggiore Policlinico - Harvest Technologies - Hospital Sao Rafael - Instituto de Medicina Regenerativa/Ageless Regenerative Institute - International Stem Cell Corporation - Medipost - Mesoblast Ltd. - NeoStem - Neuralstem - Neurogen Brain and Spine Insitute - Osiris Therapeutics - Pharmicell - Pluristem Therapeutics - ReNeuron, Ltd. - SanBio - StemCells, Inc. - Stemedica - Stempeutics - Taxus Cardium Pharmaceuticals Group - Terumo Corporation - The General Hospital of Chinese Armed Police Forces - Translational Biosciences - University of Irvine - Vericel For more information visit http://www.researchandmarkets.com/research/fg...arkets_for
CAPR: 4.09 (-0.09), PSTI: 1.35 (+0.04), CYTX: 1.98 (-0.03), OSIR: 4.86 (-0.08)
Mesoblast Chairman's Address to 2015 Annual General Meeting
GlobeNewswire - Thu Oct 22, 1:01AM CDT
Thank you for attending the Mesoblast 2015 Annual General Meeting.
Celgene and Mesoblast Extend Agreement
GlobeNewswire - Thu Oct 15, 6:49PM CDT
Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that it has agreed with Celgene Corporation to extend for a period of six months Celgene's right of first refusal with respect to Mesoblast's proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.
CELGZ: 1.35 (unch)
Global Degenerative Disc Disease Pipeline Review 2015 - 12 Companies & 15 Drug Profiles
M2 - Tue Oct 06, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rj7fth/degenerative_disc) has announced the addition of the "Degenerative Disc Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Degenerative Disc Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Degenerative Disc Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Biogenomics Limited - Bioheart, Inc. - Biopharm GmbH - BioRestorative Therapies, Inc. - Bone Therapeutics SA - Discgenics, Inc - ISTO Technologies, Inc. - K-Stemcell Co., Ltd. - Mesoblast Limited - TissueGene, Inc. - Yuhan Corporation Drug Profiles - AdipoCell - ALLOB - brtxDISC - CHND-1 - dibotermin alfa - MPC-25Osteo - NuQu - Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders - Poly N-Acetyl Glucosamine Hydrogel - Recombinant Protein for Degenerative Disc Disease, Bone Fracture, Parkinson's Disease and Erectile Dysfunction - S-414114 - Stem Cell Therapy - Stem Cell Therapy for Degenerative Disc Disease - TG-D - YH-14618 For more information visit http://www.researchandmarkets.com/research/rj...ative_disc
Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure
GlobeNewswire - Tue Sep 29, 8:10PM CDT
Mesoblast Limited (ASX: MSB; USOTC:MBLTY) today announced that additional Phase 2 trial results of its lead product candidate for the treatment of chronic heart failure (CHF) were presented at the 19th Annual Scientific Meeting of the Heart Failure Society of America in National Harbor, MD, USA held from 26-29 September. The results showed that Mesoblast's mesenchymal precursor cell (MPC) therapy had the greatest cardioprotective effect in the subset of patients with more advanced heart failure.
Full Product Approval In Japan Received By Mesoblast Licensee
GlobeNewswire - Fri Sep 18, 12:23AM CDT
Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that its licensee JCR Pharmaceuticals Co. Ltd has received full approval from the Japanese Ministry of Health, Labour and Welfare for TEMCELL(R) HS Inj. (JR-031), an allogeneic mesenchymal stem cell product.
The New Age of Regenerative Medicine - Why Stem Cell Therapy?
M2 - Wed Sep 09, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/trw352/seg3d_the_new_age) has announced the addition of the "Seg3D The New Age of Regenerative Medicine" report to their offering. Cell therapy is the fastest growing segment of the Regenerative Medicine (RM) industry. It comprises both immune cell therapy and stem cell therapy; however, stem cell therapy makes up the largest part of this segment. The global cell therapy market is driven by the success of stem cell treatments in treating or curing life-threatening diseases such as cancer, heart disease, and neuro-muscular ailments among the aging population. This research study provides an overview of the regenerative medicine industry and an insight on successful stem cell therapy treatments. It also analyses marketed products, stem cell manufacturing and funding, and the collaborative partnerships in the regenerative medicine industry. Key Findings - Regenerative Medicine (RM) represents a new human-health paradigm with the potential to resolve unmet medical needs by addressing the underlying causes of diseases. - Globally, there are over companies focused on regenerative medicine. The United States has the most registered RM companies, followed by the United Kingdom, Germany and Japan. - Rapidly growing medical tourism, contract research outsourcing, and a rising population of patients with neurological and other chronic conditions are some of the factors driving the Asian stem cells market. Key Questions This Study Will Answer - What are some of the key developments impacting the regenerative medicine industry? - What are some of the key regulatory changes affecting the regenerative medicine industry? - How are investments and market consolidations progressing in Asia-Pacific? - What are some of the key participants making an impact in the regenerative medicine industry? Key Topics Covered: - Executive Summary - The New Age of Regenerative Medicine - An Overview - Stem Cell Manufacturing Facilities - Market Dynamics - Stem Cell Consumers - Future Trends - Regenerative Medicine Industry - Mergers, Acquisitions, and Partnership Assessment - Regenerative Medicine Industry - Funding Scenario - Overview of Regenerative Medicine in Asia-Pacific - Conclusion Companies Mentioned - MEDIPOST Co., Ltd. - Mesoblast Ltd. - Cellular Dynamics International (CDI) - Orthofix International - Capricor Therapeutics For more information visit http://www.researchandmarkets.com/research/tr...he_new_age
CAPR: 4.09 (-0.09), ICEL: 16.55 (+0.03)
Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan
GlobeNewswire - Thu Sep 03, 7:44PM CDT
Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that the allogeneic mesenchymal stem cell-based regenerative medicine product JR-031, developed by Mesoblast's Japanese partner JCR Pharmaceuticals Co. Ltd., was recommended for approval on 2 September at a meeting organized by the Committee on Regenerative Medicine Products and Biological Technology of Pharmaceutical Affairs and Food Sanitation Council of the Japan Ministry of Health, Labour and Welfare. JCR said marketing approval of JR-031 is anticipated in the near future.
Type 2 Diabetes Trial Results Published In Diabetes Care
GlobeNewswire - Wed Jul 22, 6:17PM CDT
Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results of the Phase 2 trial of its intravenously-delivered Mesenchymal Precursor Cells (MPCs) for the treatment of type 2 diabetes have been published online ahead of full print in the peer-reviewed journal of the American Diabetes Association, Diabetes Care. The article is entitled "Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose Escalation Safety and Tolerability Pilot Study".
Low Back Pain Therapeutics Pipeline Review 2015 - 17 Companies & 19 Drug Profiles
M2 - Tue Jul 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrggl2/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Ipsen S.A. - MEDRx Co., Ltd. - Merck & Co., Inc. - Mesoblast Limited - Nektar Therapeutics - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Pfizer Inc. - Stayble Therapeutics - Teikoku Pharma USA, Inc. Drug Profiles - (acetaminophen tramadol hydrochloride) - (diclofenac sodium eperisone) - (etodolac lidocaine) - (etoricoxib tizanidine) - (oxycodone hydrochloride naltrexone) ER - AB-001 - abobotulinumtoxin A - ASP-7962 - Atx09-002 - bupivacaine hydrochloride - cebranopadol - Drug for Chronic Low Back Pain - duloxetine hydrochloride DR - eperisone SR - flurbiprofen sodium - MPC-06ID - NKTR-181 - oxycodone hydrochloride ER - PF-06372865 For more information visit http://www.researchandmarkets.com/research/qr..._back_pain
PFE: 35.77 (-0.09), MRK: 58.78 (-0.38), COLL: 12.50 (+0.01), LLY: 79.32 (-0.70), PCRX: 35.86 (+0.65), NKTR: 14.30 (+0.09), PTIE: 2.21 (-0.02)
Congestive Heart Failure Phase Trial Results Published In Circulation Research
GlobeNewswire - Tue Jul 14, 6:03PM CDT
Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that Phase 2 trial results of its cell therapy product candidate for the treatment of congestive heart failure (CHF) have been published in the latest edition of Circulation Research. The results were published as an "online first" article ahead of full print in this peer-reviewed, high-impact journal of the American Heart Association.
Chronic Heart Failure Pipeline Report 2015 - 16 Companies & 26 Drug Profiles
M2 - Fri Jul 10, 3:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3fzgp/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AnGes MG, Inc. - ARCA biopharma, Inc. - Bayer AG - Bial - Portela & Ca, S.A. - Celyad - Jiangsu Hengrui Medicine Co., Ltd. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - Novartis AG - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Sanofi - Stemedica Cell Technologies, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - (sacubitril valsartan) - aliskiren fumarate - BAY-1067197 - beperminogene perplasmid - BIA-51058 - BR-5489 - C3BSCQR-1 - carvedilol phosphate ER - cenderitide - F-373280 - finerenone - furosemide - ivabradine - Mesenchymal Stem Cells - MPC-150IM - Neucardin - omecamtiv mecarbil - PB-1046 - Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - rivaroxaban - RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - SAR-296968 - serelaxin - sildenafil citrate - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - vericiguat For more information visit http://www.researchandmarkets.com/research/z3...onic_heart
PFE: 35.77 (-0.09), AMGN: 156.59 (+0.54), NVS: 81.80 (-0.22), CYAD: 24.95 (-0.05)
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
GlobeNewswire - Mon Jun 08, 8:12PM CDT
Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic nephropathy showed that a single infusion of its intravenously delivered allogeneic mesenchymal precursor cell (MPC) product candidate MPC-300-IV was safe, reduced damaging inflammation, and preserved or improved renal function over at least 24 weeks.
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 0.14 (+0.01), GALT: 1.52 (-0.01), LLY: 79.32 (-0.70), GSK: 43.34 (-0.31), BMY: 74.08 (+0.22), CTIC: 0.36 (+0.02), CNCE: 11.79 (+0.12), JNJ: 122.51 (-0.13), GILD: 85.47 (-0.26), AZN: 30.11 (+0.02), CCXI: 4.82 (+0.08), ICPT: 143.75 (+0.90), ABBV: 63.43 (+0.06)
Global Spinal Stenosis Pipeline Review 2015 - 5 Companies & 6 Drug Profiles
M2 - Wed May 20, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/68zlvw/spinal_stenosis) has announced the addition of the "Spinal Stenosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Stenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Stenosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - LTT Bio-Pharma Co., Ltd. - Mesoblast Limited - Sucampo Pharmaceuticals, Inc. - Toray Industries, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - beraprost sodium SR - LT-0101 - MPC-25Osteo - SPI-017 - SPI-3608 - YLS-1501 For more information visit http://www.researchandmarkets.com/research/68...l_stenosis
SCMP: 11.39 (+0.16)
Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting
GlobeNewswire - Mon May 18, 4:39AM CDT
Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that Phase 2 trial results of its lead product candidate for the treatment of diabetic nephropathy have been selected for presentation at the late-breaking scientific sessions of the 75th American Diabetes Association (ADA) Scientific Sessions being held from June 5-9 in Boston, MA. The annual meeting is the largest diabetes meeting in the world, bringing together approximately 14,000 participants, including clinicians and researchers from 124 countries.
Mesoblast Lists On Nasdaq
GlobeNewswire - Sun Nov 15, 5:46PM CST
Mesoblast Limited (ASX:MSB) (NASDAQ:MESO) today announced it had listed on the Nasdaq Global Market on 13 November under the symbol 'MESO'.
MESO: 3.91 (-0.17), MSB: 10.35 (-0.05)
Nasdaq Welcomes Mesoblast Limited to The Nasdaq Stock Market
GlobeNewswire - Fri Nov 13, 2:59PM CST
Nasdaq, Inc. (Nasdaq:NDAQ) announced that trading of Mesoblast Limited (Nasdaq:MESO) commenced on The Nasdaq Stock Market on November 13, 2015.
MESO: 3.91 (-0.17), MSB: 10.35 (-0.05), NDAQ: 64.92 (+0.18)
Mesoblast Announces Pricing Of Public Offering On Nasdaq
GlobeNewswire - Fri Nov 13, 7:39AM CST
Mesoblast Limited (NASDAQ:MESO) (ASX:MSB), a world leader in the development of innovative cell-based medicines, today announced the pricing of its public offering of 7,479,617 American Depositary Shares (ADSs), at a public offering price of US$8.00 per ADS, before underwriting discounts and commissions. In addition, Mesoblast has granted the underwriters a 30-day option to purchase up to an additional 1,121,942 ADSs at the public offering price to cover over-allotments, if any. Mesoblast expects gross proceeds before deducting underwriting discounts and commissions and expenses of approximately US$59.8 million or A$83.9 million, or US$68.8 million or A$96.5 million if the underwriters exercise their over-allotment option. The ADSs are expected to begin trading on the Nasdaq Global Market on 13 November, 2015 under the symbol 'MESO'.
MESO: 3.91 (-0.17), MSB: 10.35 (-0.05)
Key United States Patent Granted For The Treatment Of Heart Diseases, Stroke And Other Vascular Conditions
GlobeNewswire - Tue Oct 27, 8:07PM CDT
Mesoblast Limited (ASX:MSB) (USOTC:MBLTY) today announced that the United States Patent and Trademark Office (USPTO) has granted a key patent covering the use of the Company's proprietary adult Mesenchymal Precursor Cells (MPCs) for the formation and repair of blood vessels in ischemic tissues.
MSB: 10.35 (-0.05)
U.S. Markets for Biologic and Tissue Engineered Devices 2015 - Cardiovascular and Neurological Products Analysis
M2 - Tue Oct 27, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fghmqn/u_s_markets_for) has announced the addition of the "U.S. Markets for Biologic and Tissue Engineered Devices - Cardiovascular and Neurological Products" report to their offering. Tissue engineering, or regenerative medicine, represents a promising therapeutic possibility for the treatment of aggressive and deadly diseases. Cellular therapies for cardiovascular disease (CVD) and neurological disease represent potential billion dollar markets that could offer a viable therapeutic option for a sizable patient population that has exhausted other therapeutic alternatives. Over 35 novel cellular therapies for cardiovascular and neurological disease are currently in development internationally, and in the United States (U.S.). The scope of the analysis of this report covers companies developing novel cellular therapeutics for the treatment of debilitating and deadly diseases that currently lack adequate therapeutic intervention. Cardiovascular disease-related conditions with cellular therapies in development are discussed in Chapter 2 of this report, which covers acute myocardial infarction, critical limb ischemia, heart failure, and bioengineered vascular grafts. Neurological conditions/diseases discussed in Chapter 3 of this report include Alzheimer's disease, ischemic stroke, Parkinson's disease, and spinal cord injury. Content included in this report includes: - Emerging cellular therapies for cardiovascular and neurological diseases - Companies and biotech firms developing novel cellular therapies - A prospective regulatory approval forecast for cellular therapy products currently in development for cardiovascular and neurological diseases - A speculative market analysis predicting the potential overall market values for cardiovascular and neurological disease stem cell therapies. Key Topics Covered: Executive Summary 1. Tissue Engineering and Cellular Therapy Tools and Techniques 1.1 Biomaterials 1.2 Cell Culture Technology 1.3 Stem Cell Technology 1.4 Immunoisolation Technology 2. Emerging Applications of Tissue Engineering and Cell Transplantation in Cardiovascular Disease Management 2.1 Cellular Therapy and Tissue Engineering 2.2 Cellular Therapy Administration 2.3 Clinical Experience with Stem Cell-Based Myocardial Tissue Repair and Regeneration 2.4 Cellular Therapies for Myocardial Repair and Regeneration in Development 2.5 Emerging Cellular Therapies for Limb Salvage in Critical Limb Ischemia Patients 2.6 Bioengineered Vascular Conduits 2.7 Current and Emerging U.S. Market for Cardiovascular Disease-Related Tissue Engineering and Cellular Therapy Products 3. Emerging Applications of Tissue Engineering and Cell Transplantation in Neurological Disease Management 3.1 Types of Cells Used for Cellular Therapies in Development 3.2 Emerging Stem Cell-Based Therapies for Alzheimer's Disease 3.3 Emerging Stem Cell-Based Therapies for Parkinson's Disease 3.4 Emerging Stem Cell-Based Therapies for Spinal Cord Injury 3.5 Emerging Stem Cell-Based Therapies for Post-Ischemic Stroke 3.6 Potential U.S. Market for Neurological Disease-Related Cellular Therapy Products Appendix: Company Listing Bibliography Companies Mentioned - Athersys - Baxter - Bioheart, Inc. - Biomet Biologics - Bukwang Pharmaceutical - Bundang CHA Hospital - Capricor Therapeutics - Chinese Academy of Military Medical Sciences - Cytori Therapeutics - Ecron Acunova - Fondazione IRCCS Ca'Granda, Ospedale Maggiore Policlinico - Harvest Technologies - Hospital Sao Rafael - Instituto de Medicina Regenerativa/Ageless Regenerative Institute - International Stem Cell Corporation - Medipost - Mesoblast Ltd. - NeoStem - Neuralstem - Neurogen Brain and Spine Insitute - Osiris Therapeutics - Pharmicell - Pluristem Therapeutics - ReNeuron, Ltd. - SanBio - StemCells, Inc. - Stemedica - Stempeutics - Taxus Cardium Pharmaceuticals Group - Terumo Corporation - The General Hospital of Chinese Armed Police Forces - Translational Biosciences - University of Irvine - Vericel For more information visit http://www.researchandmarkets.com/research/fg...arkets_for
CAPR: 4.09 (-0.09), PSTI: 1.35 (+0.04), CYTX: 1.98 (-0.03), OSIR: 4.86 (-0.08)
Mesoblast Chairman's Address to 2015 Annual General Meeting
GlobeNewswire - Thu Oct 22, 1:01AM CDT
Thank you for attending the Mesoblast 2015 Annual General Meeting.
Celgene and Mesoblast Extend Agreement
GlobeNewswire - Thu Oct 15, 6:49PM CDT
Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that it has agreed with Celgene Corporation to extend for a period of six months Celgene's right of first refusal with respect to Mesoblast's proprietary mesenchymal lineage adult stem cell product candidates for the prevention and treatment of acute graft versus host disease (GVHD), certain oncologic diseases, inflammatory bowel diseases, and organ transplant rejection.
CELGZ: 1.35 (unch)
Global Degenerative Disc Disease Pipeline Review 2015 - 12 Companies & 15 Drug Profiles
M2 - Tue Oct 06, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rj7fth/degenerative_disc) has announced the addition of the "Degenerative Disc Disease - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Degenerative Disc Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Degenerative Disc Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AnGes MG, Inc. - Biogenomics Limited - Bioheart, Inc. - Biopharm GmbH - BioRestorative Therapies, Inc. - Bone Therapeutics SA - Discgenics, Inc - ISTO Technologies, Inc. - K-Stemcell Co., Ltd. - Mesoblast Limited - TissueGene, Inc. - Yuhan Corporation Drug Profiles - AdipoCell - ALLOB - brtxDISC - CHND-1 - dibotermin alfa - MPC-25Osteo - NuQu - Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders - Poly N-Acetyl Glucosamine Hydrogel - Recombinant Protein for Degenerative Disc Disease, Bone Fracture, Parkinson's Disease and Erectile Dysfunction - S-414114 - Stem Cell Therapy - Stem Cell Therapy for Degenerative Disc Disease - TG-D - YH-14618 For more information visit http://www.researchandmarkets.com/research/rj...ative_disc
Phase 2 Trial Results Show Mesoblast Cell Therapy Has Greatest Cardioprotective Effect In Patients With Advanced Heart Failure
GlobeNewswire - Tue Sep 29, 8:10PM CDT
Mesoblast Limited (ASX: MSB; USOTC:MBLTY) today announced that additional Phase 2 trial results of its lead product candidate for the treatment of chronic heart failure (CHF) were presented at the 19th Annual Scientific Meeting of the Heart Failure Society of America in National Harbor, MD, USA held from 26-29 September. The results showed that Mesoblast's mesenchymal precursor cell (MPC) therapy had the greatest cardioprotective effect in the subset of patients with more advanced heart failure.
Full Product Approval In Japan Received By Mesoblast Licensee
GlobeNewswire - Fri Sep 18, 12:23AM CDT
Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that its licensee JCR Pharmaceuticals Co. Ltd has received full approval from the Japanese Ministry of Health, Labour and Welfare for TEMCELL(R) HS Inj. (JR-031), an allogeneic mesenchymal stem cell product.
The New Age of Regenerative Medicine - Why Stem Cell Therapy?
M2 - Wed Sep 09, 3:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/trw352/seg3d_the_new_age) has announced the addition of the "Seg3D The New Age of Regenerative Medicine" report to their offering. Cell therapy is the fastest growing segment of the Regenerative Medicine (RM) industry. It comprises both immune cell therapy and stem cell therapy; however, stem cell therapy makes up the largest part of this segment. The global cell therapy market is driven by the success of stem cell treatments in treating or curing life-threatening diseases such as cancer, heart disease, and neuro-muscular ailments among the aging population. This research study provides an overview of the regenerative medicine industry and an insight on successful stem cell therapy treatments. It also analyses marketed products, stem cell manufacturing and funding, and the collaborative partnerships in the regenerative medicine industry. Key Findings - Regenerative Medicine (RM) represents a new human-health paradigm with the potential to resolve unmet medical needs by addressing the underlying causes of diseases. - Globally, there are over companies focused on regenerative medicine. The United States has the most registered RM companies, followed by the United Kingdom, Germany and Japan. - Rapidly growing medical tourism, contract research outsourcing, and a rising population of patients with neurological and other chronic conditions are some of the factors driving the Asian stem cells market. Key Questions This Study Will Answer - What are some of the key developments impacting the regenerative medicine industry? - What are some of the key regulatory changes affecting the regenerative medicine industry? - How are investments and market consolidations progressing in Asia-Pacific? - What are some of the key participants making an impact in the regenerative medicine industry? Key Topics Covered: - Executive Summary - The New Age of Regenerative Medicine - An Overview - Stem Cell Manufacturing Facilities - Market Dynamics - Stem Cell Consumers - Future Trends - Regenerative Medicine Industry - Mergers, Acquisitions, and Partnership Assessment - Regenerative Medicine Industry - Funding Scenario - Overview of Regenerative Medicine in Asia-Pacific - Conclusion Companies Mentioned - MEDIPOST Co., Ltd. - Mesoblast Ltd. - Cellular Dynamics International (CDI) - Orthofix International - Capricor Therapeutics For more information visit http://www.researchandmarkets.com/research/tr...he_new_age
CAPR: 4.09 (-0.09), ICEL: 16.55 (+0.03)
Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan
GlobeNewswire - Thu Sep 03, 7:44PM CDT
Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that the allogeneic mesenchymal stem cell-based regenerative medicine product JR-031, developed by Mesoblast's Japanese partner JCR Pharmaceuticals Co. Ltd., was recommended for approval on 2 September at a meeting organized by the Committee on Regenerative Medicine Products and Biological Technology of Pharmaceutical Affairs and Food Sanitation Council of the Japan Ministry of Health, Labour and Welfare. JCR said marketing approval of JR-031 is anticipated in the near future.
Type 2 Diabetes Trial Results Published In Diabetes Care
GlobeNewswire - Wed Jul 22, 6:17PM CDT
Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results of the Phase 2 trial of its intravenously-delivered Mesenchymal Precursor Cells (MPCs) for the treatment of type 2 diabetes have been published online ahead of full print in the peer-reviewed journal of the American Diabetes Association, Diabetes Care. The article is entitled "Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose Escalation Safety and Tolerability Pilot Study".
Low Back Pain Therapeutics Pipeline Review 2015 - 17 Companies & 19 Drug Profiles
M2 - Tue Jul 21, 10:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qrggl2/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Collegium Pharmaceutical, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Ipsen S.A. - MEDRx Co., Ltd. - Merck & Co., Inc. - Mesoblast Limited - Nektar Therapeutics - Pacira Pharmaceuticals, Inc. - Paladin Labs Inc. - Pfizer Inc. - Stayble Therapeutics - Teikoku Pharma USA, Inc. Drug Profiles - (acetaminophen tramadol hydrochloride) - (diclofenac sodium eperisone) - (etodolac lidocaine) - (etoricoxib tizanidine) - (oxycodone hydrochloride naltrexone) ER - AB-001 - abobotulinumtoxin A - ASP-7962 - Atx09-002 - bupivacaine hydrochloride - cebranopadol - Drug for Chronic Low Back Pain - duloxetine hydrochloride DR - eperisone SR - flurbiprofen sodium - MPC-06ID - NKTR-181 - oxycodone hydrochloride ER - PF-06372865 For more information visit http://www.researchandmarkets.com/research/qr..._back_pain
PFE: 35.77 (-0.09), MRK: 58.78 (-0.38), COLL: 12.50 (+0.01), LLY: 79.32 (-0.70), PCRX: 35.86 (+0.65), NKTR: 14.30 (+0.09), PTIE: 2.21 (-0.02)
Congestive Heart Failure Phase Trial Results Published In Circulation Research
GlobeNewswire - Tue Jul 14, 6:03PM CDT
Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that Phase 2 trial results of its cell therapy product candidate for the treatment of congestive heart failure (CHF) have been published in the latest edition of Circulation Research. The results were published as an "online first" article ahead of full print in this peer-reviewed, high-impact journal of the American Heart Association.
Chronic Heart Failure Pipeline Report 2015 - 16 Companies & 26 Drug Profiles
M2 - Fri Jul 10, 3:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z3fzgp/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AnGes MG, Inc. - ARCA biopharma, Inc. - Bayer AG - Bial - Portela & Ca, S.A. - Celyad - Jiangsu Hengrui Medicine Co., Ltd. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mesoblast Limited - Novartis AG - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Sanofi - Stemedica Cell Technologies, Inc. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - (sacubitril valsartan) - aliskiren fumarate - BAY-1067197 - beperminogene perplasmid - BIA-51058 - BR-5489 - C3BSCQR-1 - carvedilol phosphate ER - cenderitide - F-373280 - finerenone - furosemide - ivabradine - Mesenchymal Stem Cells - MPC-150IM - Neucardin - omecamtiv mecarbil - PB-1046 - Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases - rivaroxaban - RNAi Gene Therapy to Inhibit STIM1 for Chronic Heart Failure and Atherosclerosis - SAR-296968 - serelaxin - sildenafil citrate - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - vericiguat For more information visit http://www.researchandmarkets.com/research/z3...onic_heart
PFE: 35.77 (-0.09), AMGN: 156.59 (+0.54), NVS: 81.80 (-0.22), CYAD: 24.95 (-0.05)
Postive Trial Results Of Mesoblast Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease
GlobeNewswire - Mon Jun 08, 8:12PM CDT
Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that results from the Company's Phase 2 trial in patients with diabetic nephropathy showed that a single infusion of its intravenously delivered allogeneic mesenchymal precursor cell (MPC) product candidate MPC-300-IV was safe, reduced damaging inflammation, and preserved or improved renal function over at least 24 weeks.
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 0.14 (+0.01), GALT: 1.52 (-0.01), LLY: 79.32 (-0.70), GSK: 43.34 (-0.31), BMY: 74.08 (+0.22), CTIC: 0.36 (+0.02), CNCE: 11.79 (+0.12), JNJ: 122.51 (-0.13), GILD: 85.47 (-0.26), AZN: 30.11 (+0.02), CCXI: 4.82 (+0.08), ICPT: 143.75 (+0.90), ABBV: 63.43 (+0.06)
Global Spinal Stenosis Pipeline Review 2015 - 5 Companies & 6 Drug Profiles
M2 - Wed May 20, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/68zlvw/spinal_stenosis) has announced the addition of the "Spinal Stenosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Spinal Stenosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Spinal Stenosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - LTT Bio-Pharma Co., Ltd. - Mesoblast Limited - Sucampo Pharmaceuticals, Inc. - Toray Industries, Inc. - Yungjin Pharm Ind. Co., Ltd. Drug Profiles - beraprost sodium SR - LT-0101 - MPC-25Osteo - SPI-017 - SPI-3608 - YLS-1501 For more information visit http://www.researchandmarkets.com/research/68...l_stenosis
SCMP: 11.39 (+0.16)
Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting
GlobeNewswire - Mon May 18, 4:39AM CDT
Mesoblast Limited (ASX:MSB; USOTC: MBLTY) today announced that Phase 2 trial results of its lead product candidate for the treatment of diabetic nephropathy have been selected for presentation at the late-breaking scientific sessions of the 75th American Diabetes Association (ADA) Scientific Sessions being held from June 5-9 in Boston, MA. The annual meeting is the largest diabetes meeting in the world, bringing together approximately 14,000 participants, including clinicians and researchers from 124 countries.
